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Abstract
Background: Introduction of cDNA or genomic clones of the tumor suppressor in lung cancer 1
(TSLC1) gene into the non-small cell lung cancer line, A549, reverses tumorigenic growth
properties of these cells. These results and the observation that TSLC1 is down-regulated in a
number of tumors suggest that TSLC1  functions as a critical switch mediating repression of
tumorigenesis.
Results: To investigate this mechanism, we compared growth properties of A549 with the TSLC1-
containing derivative. We found a G1/S phase transition delay in 12.2. Subtractive hybridization,
quantitative PCR, and TranSignal Protein/DNA arrays were used to identify genes whose
expression changed when TSLC1 was up-regulated. Members of common G1/S phase regulatory
pathways such as TP53, MYC, RB1 and HRAS were not differentially expressed, indicating that TSLC1
may function through an alternative pathway(s). A number of genes involved in cell proliferation
and tumorigenesis were differentially expressed, notably genes in the Ras-induced senescence
pathway. We examined expression of several of these key genes in human tumors and normal lung
tissue, and found similar changes in expression, validating the physiological relevance of the A549
and 12.2 cell lines.
Conclusion:  Gene expression and cell cycle differences provide insights into potential
downstream pathways of TSLC1 that mediate the suppression of tumor properties in A549 cells.
Background
Non-small cell lung cancer (NSCLC) includes squamous
and large cell carcinomas and adenocarcinoma. NSCLC
accounts for approximately 75% of all lung cancers diag-
nosed in the United States [1]. Genetic mutations that
activate oncogenes such as KRAS2 and NRAS [2], and loss
of function in tumor suppressors such as RB1,  TP53,
PPP2R1B, CDKN2A, and TSLC1 have been demonstrated
in NSCLC tumors [3-7].
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A549 is derived from an NSCLC adenocarcinoma and dis-
plays several properties that are characteristic of trans-
formed cells, including a short cell cycle, loss of contact
inhibition, and rapid development of tumors following
injection into athymic mice [8]. Introduction of a 1.1 Mb
YAC derivative containing the TSLC1  gene into A549
restored TSLC1 expression to normal levels, creating the
stable cell line, 12.2 [8]. 12.2 cells do not develop tumors
following injection into athymic mice. TSLC1 protein is
down-regulated or lost in NSCLC and a number of other
neoplastic diseases, including pancreatic [7], hepatocellu-
lar [7], breast [9], prostate [10], nasopharyngeal [11], gas-
tric [12], and cervical cancers [13]. Reduction or loss of
TSLC1 expression is also observed in cell lines derived
from esophageal, ovarian, endometrial, small-cell lung
and colorectal tumors [14].
The product of TSLC1 is a transmembrane glycoprotein
that forms dimers both within a cell and between adjacent
cells to promote cell-cell adhesion [15]. This protein con-
tains structural domains homologous to members of the
immunoglobulin superfamily, NCAM adhesion proteins,
and the nectin family of Ca2+-independent cell-cell adhe-
sion proteins [7,16]. It contains two protein-protein inter-
action domains that are required for tumor suppressor
activity [17]. TSLC1 interacts with the actin cytoskeleton
through DAL-1, which implies that it plays a role in cell
motility [18]. The TSLC1  gene has been isolated in a
number of different experimental paradigms and has
received multiple names as a consequence, including
IGSF4, BL2, ST17, SynCAM1, SgIGSF, RA175, and NECL2
[16,19-22].
Because TSLC1 by itself can reverse tumorigenic and met-
astatic properties of the highly aggressive A549 cell line, it
is of interest to identify downstream effectors of this
potent tumor suppressor. Identification of genes or path-
ways activated by TSLC1 would help to characterize the
molecular switch from tumorigenic to non-tumorigenic
growth. We characterized the growth differences that
result from restoration of TSLC1 expression to normal lev-
els and used a number of approaches to identify the
underlying changes in gene expression. Several genes
involved in Ras-induced senescence, endometrial stromal
cell decidualization and trophoblast implantation in the
uterus were differentially regulated. Additional genes con-
tributing to cell growth, adhesion, and energy production
showed altered expression, as well. We did not find evi-
dence that TSLC1  works through any of several previ-
ously-characterized cell cycle regulatory pathways. Several
expression changes were confirmed in the small amounts
of tumor and normal tissue obtained from histological
specimens. Thus analysis of this tumor suppressor in the
readily accessible A549/12.2 cell system may provide
insights into a new gene expression cascade involved in
suppression of transformation.
Results
TSLC1 Alters Growth Properties of A549 Cells
Introduction of the TSLC1 gene or cDNA into adenocarci-
noma-derived A549 cells restores its expression to normal
levels and suppresses many tumorigenic properties of this
line [7,8]. We extended observations about the inhibitory
effect of TSLC1 expression on A549 cell growth [8] by
showing that 12.2 cells expanded to only 28% of A549
levels after five days (Table 1 and Fig. 1). This same result
was seen with WST-1 reagent, which showed that 48 hours
after plating there was a significantly reduced number of
viable 12.2 cells relative to A549 (data not shown).
We used flow cytometry to examine how TSLC1 affects
apoptosis and cell cycle. Rates of apoptosis in A549 and
the TSLC1-expressing 12.2 cell lines were compared after
staining with annexin V. No difference was detected in the
number of apoptotic cells (Fig. 2A and 2B). Next, we
stained cells with propidium iodide and examined cell
cycle profiles of A549 and 12.2 (Fig. 2C and Table 2). The
12.2 cell line showed a significant accumulation of cells in
G1 phase (74.4%) compared to A549 (60.4%). Fewer
12.2 cells were seen in S and G2/M phase (17.2 and 8.9%,
respectively) when compared to A549 (28.2 and 11.9%,
respectively). Thus, the decreased growth rate of 12.2 is
due to reduced cell division, which occurs at least in part
to a delay at the G1/S phase checkpoint, resulting in
delayed progression into S phase.
Table 1: Expansion rate of A549 and 12.2 cell lines. Expansion rates of A549 and 12.2 cells were determined by counting cells 24 h and 
120 h after plating 5 × 104 cells. Results of two independent experiments are shown.
Cell line 24 hours 120 hours Fold Increase (120 h/24 h) Growth Upregulation 
(A549/12.2)
A549 5.73 × 104 2.27 × 106 39.7 3.40
12.2 4.53 × 104 5.28 × 105 11.7
A549 2.81 × 104 8.12 × 105 28.9 3.79
12.2 3.59 × 104 2.74 × 105 7.6Molecular Cancer 2005, 4:28 http://www.molecular-cancer.com/content/4/1/28
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Expression of Signaling Pathway Genes
Differences in growth rates and cell cycle profiles between
A549 and 12.2 led us to examine expression of several
known checkpoint and signaling pathway genes using
quantitative RT-PCR (qPCR). Alterations in the Ras/p53
pathway result in abnormal G1/S transition in some
NSCLC [23]. However, mRNA levels of HRAS, p19, RB1,
and TP53 were not substantially different between A549
and 12.2 (Table 3). The minor differences in expression
levels were not coordinately regulated in a way that would
explain lengthening of the G1/S transition in 12.2 cells.
We also examined MYC and cyclin D1 (CCND1), which
promote G1 to S phase transition. Neither CCND1 nor
MYC, its upstream regulator, were differentially expressed.
Thus, neither of these established pathways appears to be
responsible for the G1 delay.
Alterations in the Wnt/β-catenin pathway are commonly
observed in colorectal cancers and other solid tumors,
including NSCLC. We detected no differences in mRNA
levels of three upstream genes in the Wnt/β-catenin path-
way, disheveled (DVL1), adenomatosis polyposis coli
(APC), and β-catenin (CTNNB1). However, transcrip-
tional regulators downstream of β-catenin, TCF4, TCF7L2,
and LEF1, were up-regulated in the suppressed 12.2 cell
line, by 6.8-, 2.2-, and 3.4-fold, respectively (Table 3).
A549 cells are metastatic in experimental systems [24],
and elevated TSLC1 expression is correlated with lower
levels of metastasis and invasion in esophageal squamous
cell carcinoma [25]. Accordingly, we examined levels of
several genes involved in angiogenesis and metastasis.
Increased expression of the angiogenic factor, VEGF, is
correlated with metastasis and poor prognosis in solid
tumors [26]. Surprisingly, this gene was up-regulated
4.2+/-0.3 fold in the suppressed 12.2 cells. Metalloprotei-
nases have roles in various stages of primary tumor pro-
gression, invasion and metastasis. In A549 and 12.2,
matrix metalloproteinase 1 (MMP1) showed no expres-
sion difference, while tissue inhibitor of metalloprotein-
ase 1 (TIMP1) showed a small (2.2+/-0.2-fold) up-
Cell doubling assay of A549 and 12.2 cells Figure 1
Cell doubling assay of A549 and 12.2 cells. Cell number 
was counted at Day 2 and Day 5, and normalized to Day 1. 
The results of two independent experiments are shown.
Flow cytometry analysis of apoptosis and cell cycle in A549  and 12.2 Figure 2
Flow cytometry analysis of apoptosis and cell cycle in 
A549 and 12.2. Histograms of (A) A549 or (B) 12.2 cells 
stained with annexin V-FITC. Percentages are averages of 
four experiments; histograms are from one representative 
experiment. (C) Cell cycle histograms of A549 and 12.2. 
Cells were fixed, stained with propidium iodide, and analyzed 
for DNA content by flow cytometry analysis. The left peak 
represents 2N cells in G1 phase and the right peak repre-
sents 4N cells in G2/M phase.Molecular Cancer 2005, 4:28 http://www.molecular-cancer.com/content/4/1/28
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regulation in 12.2. These results show that some genes
associated with metastasis are altered by TSLC1, but not
necessarily as predicted by previously described pathways
in tumorigenic cells.
Proteomic Analysis of Transcription Factors
We characterized changes in transcription factor (TF)
expression more broadly using the TranSignal Protein/
DNA Array I (Panomics Inc., Redwood City, CA). Of the
54 TFs analyzed, 4 were down-regulated 2-fold or more in
the 12.2 line and 8 were up-regulated in 12.2 (Table 3). In
general, those up-regulated in 12.2 have been previously
associated with repression of tumorigenesis. E2F1, which
regulates the G1/S phase transition and has tumor
suppressor properties, is increased in 12.2, consistent with
our results from cell cycle analysis. The signal transducer
and activator of transcription (Stat) proteins, which pro-
mote cellular proliferation, were down-regulated in 12.2.
Interestingly, several TFs commonly disregulated in can-
cer, including AP-1, c-Myb, Ets, Sp1, Myc-associated factor
X, NFκB and p53, were not altered between A549 and
12.2. (For complete list of TFs analyzed, see http://
www.panomics.com/PDarray1_references.htm. These
results are consistent with qPCR expression analysis,
which did not show differences in cDNA levels for TP53,
MYC, and ETS2 (Table 3).
Differential gene expression analysis
Subtractive hybridization was performed between A549
cells and the suppressed 12.2 cells to identify genes
differentially expressed when TSLC1 is restored to normal
levels. The procedure was performed in both directions to
produce two populations of cDNA enriched for messages
up-regulated in A549 or in 12.2, respectively. Each of the
differentially expressed cDNA populations was hybrid-
ized to Genome Systems cDNA arrays, identifying 41
genes greatly over-expressed in the tumorigenic A549 line
and 18 genes over-expressed in the suppressed 12.2 cell
line (Table 3). The differentially expressed genes repre-
sented a variety of functional classes, including those with
roles in cell proliferation, cell survival, protein phosphor-
ylation, immune response, cell adhesion, or detoxifica-
tion. Several genes whose products are localized to the
mitochondria were also differentially expressed.
Relative transcript levels for 31 of the differentially-
expressed genes were quantified using qPCR (Table 3).
Expression was normalized to glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) and alpha-tubulin
(TUBA1). qPCR showed that TSLC1 expression was 2.8+/
-0.8 times higher in 12.2 than in A549, as expected.
Twenty-one of the 31 genes analyzed by qPCR showed
expression differences of 2-fold or more in the direction
predicted by subtractive hybridization. One gene, comple-
ment component C5 (CCC5), showed a 13.8+/-4.7-fold
down-regulation in 12.2 cells, contrary to results expected
after subtractive hybridization. The nine remaining genes
changed less than 2-fold.
Several genes involved in cellular proliferation were
among those expressed at high levels in A549 but low lev-
els in 12.2 (Table 3). Cadherin 11 (CDH11), which plays
a role in cell-cell interactions was also down-regulated in
12.2. Furthermore, several mitochondrial genes were
down-regulated in 12.2 (Table 3). The genes that were
most highly up-regulated with the restoration of TSLC1
expression in 12.2 cells were the candidate tumor suppres-
sor Ras-induced senescence 1 (RIS1), metallothionein 1G
(MT1G) and metallothionein 1E (MT1E).
Gene expression in tumor vs. normal tissue
We compared gene expression in normal vs. tumor tissue
to determine whether differences in 12.2 and A549 cells
reflect changes that occur in vivo (Table 4). Tissue was
recovered from pathological specimens and transcript lev-
els were measured by qPCR, normalized to GAPDH as
described [14]. TSLC1 and RIS1 levels were lower than
normal in 5/5 tumor specimens, while S100 calcium-
binding protein P (S100P) and insulin-like growth factor
binding protein 1 (IGFBP1) levels were elevated in 5/5
and 4/5 tumors, respectively. Thus, key differences
observed between the transformed (A549) and sup-
pressed (12.2) cell lines reflect physiological differences
seen in tumor vs. normal tissue.
Discussion
Restoration of TSLC1 expression to normal levels in A549
cells reverses several transformed properties of this line,
slowing the growth rate, restoring contact inhibition,
eliminating its ability to form tumors in nude mice and
blocking metastasis. In this study, we have shown that res-
toration of TSLC1 expression in 12.2 cells reduced cell
growth by 3.6-fold. This change in growth rate dynamics
was not due to an increase in the number of apoptotic
cells. Rather, flow cytometry revealed that 12.2 cells expe-
Table 2: Cell cycle profiles of cell lines determined by flow 
cytometry. Flow cytometry analysis of cell cycle profiles was 
determined for A549 and 12.2. Percentages were quantified 
using CellQuest software. A549 and 12.2 profiles are the means 
of three experiments. The difference between A549 and 12.2 is 
statistically significant (p < 0.005).
Cell Cycle Stage Percent Total Cells
A549 12.2
G1 60.4+/-0.3 74.4+/-1.8
S 28.2+/-0.5 17.2+/-2.3
G2/M 11.9+/-0.7 8.9+/-1.0Molecular Cancer 2005, 4:28 http://www.molecular-cancer.com/content/4/1/28
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Table 3: Comparison of gene expression in A549 and 12.2 cell lines. Genes expressed differentially between A549 and 12.2 cells were 
identified by qPCR, subtractive hybridization (SH), and/or TransSignal DNA-protein array (TS) as indicated. Relative quantification 
differences were determined for those genes analyzed by either qPCR or TS. ND, not determined.
Gene Up-Regulated Assay Fold Expression 
Difference
Functional Class
Fibrinogen beta chain (FGB) A549 SH/qPCR 2737.5+/-1058.5 Adhesion
Fibrinogen gamma chain (FGG) A549 SH ND Adhesion
Adenomatosis polyposis coli (APC)* A549 qPCR 1.7+/-0.2 Cellular Growth
Cyclin D1 (CCND1)† A549 qPCR 1.6+/-0.0 Cellular Growth
β-catenin 1 (CTNNB1)* 12.2 qPCR 1.1+/-0.0 Cellular Growth
Dishevelled 1 (DVL1)* A549 qPCR 1.1+/-0.3 Cellular Growth
v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
(HRAS)†
A549 qPCR 1.4+/-0.3 Cellular Growth
Lymphoid enhancer-binding factor 1 (LEF1)* 12.2 qPCR 3.4+/-0.4 Cellular Growth
v-myc myelocytomatosis viral oncogene homolog 
(MYC)†
A549 qPCR 1.3+/-0.2 Cellular Growth
Interleukin 23-alpha (p19)† A549 qPCR 1.0+/-0.0 Cellular Growth
Tumor protein p53 (TP53)† A549 qPCR 1.7+/-0.3 Cellular Growth
Retinoblastoma 1 (RB1)† 12.2 qPCR 1.3+/-0.4 Cellular Growth
S100 calcium-binding protein P (S100P) A549 SH/qPCR 1680.0+/-955.4 Cellular Growth
Transcription factor 4 (TCF4)* 12.2 qPCR 6.8+/-2.0 Cellular Growth
Transcription factor 7-like 2 (TCF7L2)* 12.2 qPCR 2.2+/-0.7 Cellular Growth
Transmembrane 4 superfamily member (TM4SF4) A549 SH/qPCR 475.2+/-328.0 Cellular Growth
Centromere protein E (CENPE)A 5 4 9 S H C e l l u l a r  G r o w t h
Heat shock protein 70B (HSPA6) A549 SH/qPCR 2.4+/-0.8 Chaperone
Insulin-like growth factor binding protein 1 (IGFBP1) A549 SH/qPCR 15.9+/-7.4 Decidualization [41]
Retinoid X receptor RXR (DR-1) A549 TS 2.7 Decidualization [42]
Aldehyde dehydrogenase 1 (ALDH1) A549 SH/qPCR 4.2+/-0.1 Decidualization-Implantation [43]
Annexin A2 (Lipocortin II) (ANXA2) 12.2 SH/qPCR 3.1+/-1.0 Decidualization-Implantation [43]
Metallothionein-IF (MTIF) 12.2 SH ND Decidualization-Implantation [43]
Metallothionein-IG (MT1G) 12.2 SH/qPCR 37.1+/-10.4 Decidualization-Implantation [43]
Cadherin 11 (OB-cadherin, osteoblast) (CDH11) A549 SH/qPCR 5.6+/-2.7 Decidualization-Luteal/Adhesion 
[34,44]
Fibroblast growth factor 9 (FGF9) A549 SH ND Decidualization-Proliferation [45]
Promyelocytic leukemia gene (PML) A549 SH ND Decidualization-Proliferation
Similar to aldehyde dehydrogenase 6 (ALDH1A3)A 5 4 9 S H N D D e h y d r o g e n a s e
3-alpha hydroxysteroid dehydrogenase type II 
(AKR1C3)
A549 SH ND Dehydrogenase
Dihydrodiol dehydrogenase 2 (AKR1C2) A549 SH/qPCR 22.9+/-2.4 Dehydrogenase
Kinesin 2, light chain (KNS2) 12.2 SH/qPCR 3.9+/-0.0 Intracellular Trafficking
Matrix metalloproteinase 1 (MMP1) 12.2 qPCR 1.2+/-0.4 Invasion
Vascular endothelial growth factor (VEGF) 12.2 qPCR 4.2+/-0.3 Invasion
Ferritin, heavy chain (FTH1) 12.2 SH/qPCR 2.7+/-1.7 Iron Binding
Metallothionein-IE (MT1E) 12.2 SH/qPCR 14.8+/-8.5 Metal Homeostasis
Metallothionein-IH (MT1H) 12.2 SH ND Metal Homeostasis
Metallothionein-IL (MT1L) 12.2 SH/qPCR 5.8+/-0.9 Metal Homeostasis
Metallothionein-IR (MT1R) 12.2 SH ND Metal Homeostasis
Manganese-containing superoxide dismutase (SOD2) A549 SH/qPCR 2.0+/-0.6 Mitochondrial
Microsomal glutathione transferase (MGST1) A549 SH/qPCR 2.3+/-0.1 Mitochondrial
NAD(P)H menadione oxidoreductase 1, dioxin-inducible 
(NQO1)
A549 SH/qPCR 3.1+/-0.1 Mitochondrial
Solute carrier family 25 member 5 (SLC25A5) A549 SH/qPCR 3.4+/-0.3 Mitochondrial
Myelin proteolipid protein (PLP) A549 SH ND Myelin Constituent
Ribosomal protein S6 (RPS6) 12.2 SH/qPCR 2.5+/-1.2 Protein Kinase
v-ets erythroblastosis virus E26 oncogene homolog 2 
(ETS2)
A549 qPCR 1.2+/-0.0 Ras-Induced Senescence [29]
Metallothionein-II (MTII) 12.2 SH ND Ras-Induced Senescence [29]
Ras induced senescence 1 (RIS1) 12.2 SH/qPCR 80.2+/-62.3 Ras-Induced Senescence [29]
Tissue inhibitor of metalloproteinase 1 (TIMP1) 12.2 qPCR 2.2+/-0.1 Ras-Induced Senescence [29]
CAAT box general (CBF) 12.2 TS 2.5 Transcription Factor
CCAAT displacement protein (CDP) 12.2 TS 2 Transcription Factor
E2F transcription factor 1 (E2F-1) 12.2 TS 2.4 Transcription FactorMolecular Cancer 2005, 4:28 http://www.molecular-cancer.com/content/4/1/28
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rience a delay relative to A549 cells in progression from
G1 to S phase of the cell cycle. These differences in growth
related properties between A549 and 12.2 were similar to
those observed previously when tumor cells were trans-
fected with a vector containing TSLC1 cDNA or genomic
clone [7,8,25]. These phenotypic differences led us to
examine expression of genes associated with adhesion,
invasion, basal metabolism, cell growth, senescence and
Early growth response (EGR) 12.2 TS 3.4 Transcription Factor
Estrogen receptor (ERE) 12.2 TS 2.5 Transcription Factor
GATA binding protein (GATA) 12.2 TS 2.1 Transcription Factor
Glucocorticoid receptor (GRE) 12.2 TS 3 Transcription Factor
Nuclear factor of activated T-cells, cytoplasmic (NF-
ATc)
12.2 TS 3.1 Transcription Factor
Signal transducer and activator or transcription 3 
(STAT3)
A549 TS 2 Transcription Factor
Signal transducer and activator or transcription 4 
(STAT4)
A549 TS 2.3 Transcription Factor
Upstream transcription factor (USF-1) A549 TS 2.5 Transcription Factor
Transcription co-activator Sp110 A549 SH ND Transcription Factor
Similar to eukaryotic translation initiation factor 2B, 
subunit 1 (EIF2B1)
A549 SH ND Translation
Insulin-like 4 (INSL4) A549 SH/qPCR 27.0+/-15.8 Trophoblast [46]
Keratin 8 (KRT8) A549 SH ND Trophoblast [47]
cDNA clone DKFZp761C1(AL157447) A549 SH ND Unknown
cDNA clone FLJ20643 (AK000650) A549 SH ND Unknown
FLJ14639 (NM_032815) A549 SH ND Unknown
Hit clone 451B21 (AL033522) A549 SH ND Unknown
HSA1p34 genomic sequence (AL009181) A549 SH ND Unknown
Rhomboid family 1 (Z69719) (RHBDF1)A 5 4 9 S H N D U n k n o w n
RP11-2H8 (AC089984) A549 SH ND Unknown
RP11-389E6 (AL359836) A549 SH ND Unknown
RP11-478J18 (AC011700) A549 SH ND Unknown
RP11-7F24 (AC018841) A549 SH ND Unknown
RP1-20C7 (AL136304) A549 SH ND Unknown
SR+89 (Z69706) A549 SH ND Unknown
HSA14 genomic sequence (AL135745) 12.2 SH ND Unknown
* Wnt/β-catenin pathway
†G1/S transition
Table 4: Gene expression profiles in NSCLC tumor vs. normal lung parallel those in A549 and 12.2 Relative fold expression differences, 
determined by qPCR, were determined in tumors and compared to normal lung tissue from same patient. Positive values represent 
higher expression in tumor; negative values represent higher expression in normal tissue.
Relative Gene Expression in Tumors
TSLC1 RIS1 S100P IGFBP1
Patient 1 -25.7 -2.3 33.3 600
Patient 2 -23.8 -6.4 2.1 2.3
Patient 3 -16.9 -7.1 28.1 -8.4
Patient 4 -344.3 -43.9 3.2 6.1
Patient 5 -32.4 -44.9 16.1 1.9
Cell Lines Down in A549 Down in A549 Up in A549 Up in A549
Table 3: Comparison of gene expression in A549 and 12.2 cell lines. Genes expressed differentially between A549 and 12.2 cells were 
identified by qPCR, subtractive hybridization (SH), and/or TransSignal DNA-protein array (TS) as indicated. Relative quantification 
differences were determined for those genes analyzed by either qPCR or TS. ND, not determined. (Continued)Molecular Cancer 2005, 4:28 http://www.molecular-cancer.com/content/4/1/28
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apoptosis in A549 and 12.2 to identify classes of genes
altered by restoration of TSLC1 expression in 12.2.
The most highly up-regulated gene in 12.2 cells was the
putative tumor suppressor, Ras-induced senescence 1
(RIS1). RIS1 is located at 3p21.3, which is a region that is
deleted in many human tumors [27]. Also, RIS1 is located
within a 1 Mb human chromosomal region that is com-
monly deleted during tumor formation in human/mouse
microcell hybrids that are passaged through severe com-
bined immunodefficient (SCID) mice [28]. This region,
called chromosome 3 common eliminated region 1
(CER1), has been posited to contain one or more cur-
rently unidentified tumor suppressors. Our results pro-
vide support for RIS1 as a candidate.
Coordinate up-regulation of RIS1, metallothionein II, and
TIMP1 was observed in Ras-induced senescent cells [29].
Consistent with this study, we found increased levels of
RIS1, several metallothioneins, and TIMP1 in 12.2 cells.
Activation of these genes suggests that TSCL1-mediated
inhibition of tumorigenesis may be related to the Ras-
induced senescence pathway. However, previous studies
showed that RIS1 expression is dependent on ETS2, an
inducer of Ras-induced senescence, in human fibroblast
IMR90 cells [29]. ETS2 was not differentially expressed
between A549 and 12.2 cells in this study (Table 3) sug-
gesting that RIS1 is activated in 12.2 cells through a differ-
ent pathway.
Several genes were identified that have known roles in
cancer.  S100P, which was down-regulated in the non-
tumorigenic 12.2 cell line, is involved in cell growth and
has been previously implicated in prostate [30] and breast
cancer progression [31]. It is over-expressed in lung aden-
ocarcinomas [32], which frequently exhibit reduced levels
of  TSLC1  expression[7]. However, down-regulation of
S100P in A549 using antisense RNA was not sufficient to
alter growth related phenotypes by itself (data not
shown). Insulin-like growth factor 4 (INSL4), also down-
regulated in 12.2, has been reported to be over-expressed
in highly invasive breast cancer cells [33]. Reduced expres-
sion of S100P and INSL4 in 12.2 may contribute to the
slower growth rate and loss of tumorigenic properties in
the 12.2 cell line when TSLC1 expression is restored to
normal levels.
Several differentially expressed genes identified in this
study have been previously shown, in non-overlapping
experiments, to be differentially expressed during various
stages of endometrial stromal cell decidualization and tro-
phoblast implantation (Table 3). The relationship
between these processes and neoplastic transformation in
NSCLC is not clear. However, it is interesting that these
seemingly unrelated events show similar patterns of gene
expression changes. Decidualization and implantation
are characterized by high levels of proliferation and tissue
invasion; properties shared with transformed cells.
Together, these observations suggest that TSLC1  may
repress transformed growth via some of the same path-
ways that regulate proliferation in endometrial cells dur-
ing various stages of decidualization.
Subtractive hybridization and qPCR showed that restora-
tion of TSLC1 lowered expression of CDH11, an adhesion
protein that may enhance cellular invasion [34]. CDH11
is expressed in highly invasive but not in noninvasive
breast cancer cell lines [34,35]. It has been shown to asso-
ciate with β-catenin (CNNTB1)[36]. While we did not see
a significant difference in expression of upstream genes in
the Wnt-1/β-catenin pathway (DVL1, CDKN2A,
CNNTB1) between A549 and 12.2, we did see expression
differences in CTNNB1-dependent transcription factors
LEF1,  TCF4, and TCF7L2, which were up-regulated in
12.2. This may be a consequence of down-regulation of
CDH11 leading to lower levels of CNNTB1 sequestered at
the plasma membrane. This unbound CNNTB1  could
then translocate to the nucleus to activate downstream
genes. Retera et. al. [37] demonstrated that CNNTB1
expression is reduced in NSCLC primary tumors and
metastases. Our results suggest that downstream effectors
of CNNTB1, such as LEF1, TCF4, and TCF7L2, may be
involved in suppressing tumorigenic properties in 12.2.
Although the growth difference in A549 and 12.2 is char-
acterized by a significant delay at G1/S in the latter, we did
not find significant changes in gene expression for com-
mon G1/S phase regulators HRAS, p19, RB1, TP53, MYC,
and CCND1. Also, the increased expression of VEGF in
12.2 cells contrasts with observations from many tissues
which show that this gene is up-regulated in tumor cells.
This suggests that TSLC1 does not suppress tumorigenesis
through any of these common pathways. However, sev-
eral of these genes are regulated at the protein level or
through localization to the nucleus. In order to address
this concern, we examined c-Myc and cyclin D1 protein
levels by western blot, and found no difference in expres-
sion between A549 and 12.2 (data not shown). Further-
more, the Panomics TranSignal Protein/DNA Array found
no difference in expression of Myc-associated factor X,
NFκB, c-Myb, and AP-1.
Cell lines are artifactual by definition, and they do not
perfectly replicate in vivo conditions. However, compari-
son of key gene expression patterns in matched tumor-
normal tissue pairs showed that our results with A549 and
12.2 are representative of in vivo expression levels. These
results validate the physiological relevance of our in vitro
expression analysis in a model system that is far moreMolecular Cancer 2005, 4:28 http://www.molecular-cancer.com/content/4/1/28
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amenable to experiment than is the minute amount of
material recovered from histological specimens.
It is notable that acute expression of high levels of TSLC1
in A549 cells has a somewhat different effect on cell cycle
profiles than does the long-term restoration of this gene in
12.2 cells. Infection for 3 or 5 days with adenovirus vec-
tors expressing a TSLC1 cDNA (Ad-TSLC1) induced apop-
tosis and increased annexin V staining in infected cultures
[38]. This contrasts with stable restoration of TSLC1
expression in the 12.2 line, which does not demonstrate
elevation in annexin V staining. Since the 12.2 cell line
was selected after transfection of TSLC1, it adds valuable
insights into the normal function of TSLC1 in non-trans-
formed cells. TSLC1 has the ability to suppress the trans-
formed growth properties of A549, and it alters the gene
expression profile of A549 to resemble that of normal rel-
ative to transformed lung tissue. A part of its normal func-
tion as a potent tumor suppressor may be to regulate cell
growth by initiating apoptosis in those rare cells that ini-
tiate neoplastic transformation.
Conclusion
Restoration of TSLC1 levels in the tumorigenic A549 cell
line resulted in a loss of transformed growth properties,
including a reduced cell doubling rate and a delayed
progression from G1 to S phase during the cell cycle. This
corresponded with a change in the gene expression pro-
file, including changes in genes with roles in Ras-induced
senescence and endometrial decidualization. Other genes
with roles in cell proliferation were also altered when
TSLC1 levels were restored, including IGFBP1, S100P, and
INSL4. TSLC1 does not appear to act through any of sev-
eral well-characterized cell growth regulatory pathways.
Elucidating the mechanisms by which TSLC1  represses
tumorigenesis would have an important impact on the
understanding of cancer biology in the lung, as well as in
the numerous other tissues where TSLC1 has been associ-
ated with cancer progression. This study reveals several
cellular phenotypes associated with TSLC1 expression and
provides insights into the genes and molecular pathways
induced by TSLC1.
Methods
Cell Culture and Tumor Samples
The A549 cell line (American Type Culture Collection
[ATCC], Manassas, VA) was cultured in Dulbecco's modi-
fied Eagle's medium (Invitrogen Corp., Carlsbad, CA)
supplemented with 10% fetal bovine serum (Hyclone
Laboratories, Inc., Logan UT), 1X non-essential amino
acids and 1% penicillin-streptomycin (Invitrogen Corp.,
Carlsbad, CA) in 5% CO2. The suppressed 12.2 cell line
was created by transfecting YAC derivative y939-95 into
A549 cells [8]. 12.2 cells were cultured under the same
conditions as A549, with the addition of 500 µg/ml G418
(Mediatech, Inc., Herndon, VA), except for cell growth
assays, in which G418 was omitted.
For the growth assays, duplicate aliquots of 5 × 104 cells
were plated in six-well dishes. After 24, 48, and 120 h,
cells were trypsinized and three aliquots from each well
were counted using a hemacytometer. The average of six
counts (three each, for two wells) is reported here.
For the WST-1 cellular proliferation assay (Roche Applied
Science, Indianapolis, IN), 1 × 104 cells were cultured for
48 h. Samples were incubated with WST-1 reagent for 1 h,
and absorbance was measured at 450 nm and 620 nm.
Five primary NSCLC tumors and corresponding non-can-
cerous lung tissues from the same patients were surgically
resected and histologically diagnosed at National Cancer
Center, Japan. All samples were immediately frozen after
surgical resection and stored at -135°C. The analyses of
human samples were carried out in accordance with the
institutional guidelines.
Proteomic Analysis
Proteomic analysis was performed using the TranSignal
Protein/DNA Array I (Panomics Inc., Redwood City, CA).
Nuclear protein extracts from A549 or 12.2 were incu-
bated with an excess of biotinylated cis-binding elements
(CBE) of 54 common transcription factors (TFs).
Unbound CBE were removed and the protein/DNA com-
plexes were separated, leaving labeled CBE which repre-
sent the relative protein levels of the 54 TFs. These were
hybridized to a DNA array and visualized using streptavi-
din-HRP. Hybridized probe was quantified using the
AlphaImager v5.5 software (Alpha Innotech Corp. San
Leandro, CA).
Subtractive Hybridization
Total RNA was isolated from A549 and 12.2 using Trizol
reagent (Invitrogen Corp.), and poly(A) mRNA was puri-
fied using the PolyATract mRNA Isolation System II
(Promega, Madison, WI). Subtractive hybridization was
performed between A549 and 12.2 in both directions
using the PCR-Select cDNA Subtraction Kit (Clontech,
Palo Alto, CA).
The enriched pools of cDNA were hybridized to human
Gene Discovery Array cDNA nylon filters (Genome Sys-
tems, Inc., St. Louis, MO). Samples (15 µl) of the final
PCR reaction from each subtractive hybridization reaction
were radioactively labeled by random prime-labeling with
[32P]dCTP [39,40] and purified using ProbeQuant G-50
Sephadex columns (Amersham Pharmacia Biotech, Inc.,
Piscataway, NJ). The filters were prehybridized for 2 h at
42°C in buffer consisting of 0.75 M NaCl, 0.1 MMolecular Cancer 2005, 4:28 http://www.molecular-cancer.com/content/4/1/28
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Na2HPO4, 0.1% Na4P2O7-10H2O, 0.15 M Tris (pH 7.5),
5X Denhardt's solution, 2% SDS, and 100 µg/ml sheared
salmon testis DNA (Sigma-Aldrich, St. Louis, MO). Probes
were hybridized overnight at 42°C in the same buffer.
The membranes were washed in 2X SSC for 5 min at room
temperature, twice in 2X SSC with 1% SDS for 30 min at
68°C, and twice in 0.6X SSC with 1% SDS for 30 min at
68°C. The filters were then rinsed in room-temperature
2X SSC and placed on film for 3 days for the A549 over-
expressed population and 2 weeks for the 12.2 over-
expressed isolates. Identities of associated EST sequences
for positive clones were obtained from the Genome Sys-
tems website http://reagents.incyte.com/GDA/
geneID.html. EST sequences were analyzed by BLAST,
using the non-redundant database to obtain gene annota-
tion for positive clones.
Quantitative PCR
RNA was isolated from A549, 12.2, or the antisense clones
with Trizol reagent (Invitrogen Corp.) and used to gener-
ate cDNA using Superscript II reverse transcriptase (Invit-
rogen Corp.). Quantitative PCR (qPCR) was carried out
using the LightCycler rapid thermal cycler system and the
SYBR Green FastStart PCR kit (Roche Diagnostics Ltd.,
Lewes UK). Primers were used at 0.5 µM and MgCl2 at 4
mM. Samples were heat-denatured for 10 min., then
cycled 55 times at 95°C for 10 sec., 58°C for 5 sec., and
72°C for 20 sec. At the completion of the cycling, a melt-
ing curve analysis was performed to detect the presence of
multiple products. A standard curve was generated based
on serial dilutions of PAC 66B10 and primers for marker
66B10.SP6 (CCTGGTAGTGGATTTCCCAA and
ATGCCATTCAGTTTGTTCCC). Samples were normalized
to glyceraldehyde 3-phosphate (ACCACAGTCCAT-
GCCATCAC and TCCACCACCCTGTTGCTGTA). Primers
for each gene were designed using the Primer3 program
http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3.cgi.
Flow Cytometry
For the apoptosis assay, A549 and 12.2 cells were grown
without antibiotic selection. Cells were trypsinized and
stained with annexin V and propidium iodide as recom-
mended (BD Biosciences Pharmingen, San Diego, CA).
Cells were analyzed on a Becton Dickinson FACScan.
For cell cycle studies, 2 × 106 cells were collected and
resuspended in 1 ml cold PBS, and 4 ml of -20°C 100%
ethanol was slowly added. Cells were stored at -20°C
overnight, recovered by centrifugation and resuspended
in 1 ml PBS. RNase A (20 µg/ml) (Sigma-Aldrich Chemi-
cal Co., St. Louis, MO) was added, and the samples were
incubated at 37°C for 30 min. Samples were incubated in
100  µg/ml propidium iodide (Sigma-Aldrich Chemical
Co.) at room temperature for at least 1 h prior to analysis
on a Becton Dickinson FACScan.
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